228 related articles for article (PubMed ID: 20300966)
1. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.
Straver ME; Meijnen P; van Tienhoven G; van de Velde CJ; Mansel RE; Bogaerts J; Duez N; Cataliotti L; Klinkenbijl JH; Westenberg HA; van der Mijle H; Snoj M; Hurkmans C; Rutgers EJ
Ann Surg Oncol; 2010 Jul; 17(7):1854-61. PubMed ID: 20300966
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
3. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
[TBL] [Abstract][Full Text] [Related]
4. Axillary tumour burden in women with a fine-needle aspiration/core biopsy-proven positive node on ultrasonography compared to women with a positive sentinel node.
Lloyd P; Theophilidou E; Newcombe RG; Pugh L; Goyal A
Br J Surg; 2017 Dec; 104(13):1811-1815. PubMed ID: 28991362
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome.
Donker M; Straver ME; van Tienhoven G; van de Velde CJ; Mansel RE; Litière S; Werutsky G; Duez NJ; Orzalesi L; Bouma WH; van der Mijle H; Nieuwenhuijzen GA; Veltkamp SC; Helen Westenberg A; Rutgers EJ
Eur J Cancer; 2013 Jun; 49(9):2093-100. PubMed ID: 23522754
[TBL] [Abstract][Full Text] [Related]
7. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
[TBL] [Abstract][Full Text] [Related]
8. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.
Newman EA; Sabel MS; Nees AV; Schott A; Diehl KM; Cimmino VM; Chang AE; Kleer C; Hayes DF; Newman LA
Ann Surg Oncol; 2007 Oct; 14(10):2946-52. PubMed ID: 17514407
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy in breast cancer New indications and our experience.
Zanghì G; Rinzirillo NM; Caponnetto AM; Vecchio R; Catania V; Leanza V
Ann Ital Chir; 2015; 86():508-12. PubMed ID: 26898363
[TBL] [Abstract][Full Text] [Related]
11. Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer.
Cotarelo CL; Zschöck-Manus A; Schmidt M; Schad A; Brochhausen C; Kirkpatrick CJ; Thaler S
Clin Exp Metastasis; 2021 Feb; 38(1):61-72. PubMed ID: 33249518
[TBL] [Abstract][Full Text] [Related]
12. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
[TBL] [Abstract][Full Text] [Related]
13. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy.
Rydén L; Chebil G; Sjöström L; Pawlowski R; Jönsson PE
Eur J Surg Oncol; 2007 Feb; 33(1):33-8. PubMed ID: 17174513
[TBL] [Abstract][Full Text] [Related]
14. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.
Mamtani A; Patil S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Aug; 24(8):2182-2188. PubMed ID: 28429197
[TBL] [Abstract][Full Text] [Related]
15. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
Goyal A; Newcombe RG; Chhabra A; Mansel RE
Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
[TBL] [Abstract][Full Text] [Related]
16. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
17. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
[TBL] [Abstract][Full Text] [Related]
18. Discordance of intraoperative frozen section analysis with definitive histology of sentinel lymph nodes in breast cancer surgery: complementary axillary lymph node dissection is irrelevant for subsequent systemic therapy.
Geertsema D; Gobardhan PD; Madsen EV; Albregts M; van Gorp J; de Hooge P; van Dalen T
Ann Surg Oncol; 2010 Oct; 17(10):2690-5. PubMed ID: 20422461
[TBL] [Abstract][Full Text] [Related]
19. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
[TBL] [Abstract][Full Text] [Related]
20. Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy.
Mustać E; Matusan-Ilijas K; Marijić B; Smokvina M; Jonjić N
Int J Surg Pathol; 2010 Feb; 18(1):36-41. PubMed ID: 19448065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]